chronic atrophic gastritis
Conditions
Interventions
Weierkang tablet treatment group:None
Sponsors
Xijing Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, gender is not limited; 2. Patients diagnosed with moderate to severe atrophy and/or intestinal metaplasia by upper gastrointestinal endoscopy and gastric mucosal biopsy (at least 1 in gastric antrum and 1 in gastric corpus) within the past three months, namely OLGA/OLGIM II - Patients with stage IV (moderate or more atrophy/metaplasia in at least one part of the gastric antrum and corpus), including those with low-grade intraepithelial neoplasia, and those with high-grade intraepithelial neoplasia who are reluctant to undergo surgical treatment; 3. No H. pylori infection or successful eradication confirmed by 13C-UBT; 4. Voluntarily accept treatment with Weierkang tablets.
Exclusion criteria
Exclusion criteria: 1. History of gastric surgery (including ESD, EMR) or malignant tumor; 2. Patients with contraindications to the study drug or allergic to the study drug; 3. Pregnant and lactating women; 4. History of drug abuse or alcohol abuse in the past 1 year; 5. People with mental disorders; 6. Those who cannot cooperate with the completion of the treatment plan; 7. Refuse to sign the informed consent; 8. Patients who are participating in other clinical trials; 9. Patients who the researchers believe are not suitable for clinical observational studies for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathological biopsy of gastric mucosa;gastroscopy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal symptom Rating Scale; | — |
Countries
China
Contacts
Public ContactShi Yonquan
Xijing Hospital of Air Force Military Medical University
Outcome results
None listed